Company Logo
LX-9211's novel oral, non-opioid mechanism, positive Phase II data and Phase III progress position it to address unmet neuropathic pain needs and create partnering opportunities
Dublin, Sept. 25, 2026 (GLOBE NEWSWIRE) -- "LX-9211 Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The "LX-9211 Sales Forecast and Market Size Analysis - 2034" report provides a comprehensive assessment of pilavapadin (LX-9211), Lexicon Pharmaceuticals' investigational oral therapy for neuropathic pain. The analysis covers the United States, EU4 countries comprising Germany, France, Italy and Spain, the United Kingdom, and Japan, collectively referred to as the seven major markets (7MM).
The report evaluates the commercial outlook, clinical development, regulatory milestones, competitive positioning and forecasted sales of LX-9211 through 2034. Key potential indications include diabetic peripheral neuropathic pain, broader neuropathic pain populations and postherpetic neuralgia. LX-9211 remains investigational and has not received regulatory approval.
Key Factors Supporting the LX-9211 Market Opportunity
Novel mechanism of action: LX-9211 is a selective adaptor-associated kinase 1 (AAK1) inhibitor designed to modulate neuropathic pain signaling without directly targeting opioid pathways. Its differentiated mechanism may support competitive positioning against opioids, gabapentinoids and other established pain therapies.
Phase II clinical evidence: In the RELIEF-DPN-1 Phase II study, the lower-dose group achieved a pain-score reduction of 1.39 points compared with 0.72 points for placebo, with a reported p-value of 0.007. The subsequent PROGRESS Phase IIb study enrolled approximately 496 adults with moderate to severe diabetic peripheral neuropathic pain and generated additional efficacy and tolerability data.
Late-stage development potential: Lexicon selected a 10 mg once-daily dose for further development based on the overall efficacy and tolerability profile. Approximately 600 participants have been exposed to LX-9211 across Phase II programs, strengthening the available clinical dataset and supporting late-stage development planning.
Substantial unmet need: Diabetic peripheral neuropathic pain affects an estimated 9 million people in the United States. Many patients experience inadequate relief, treatment-limiting adverse effects or repeated therapy changes, creating demand for differentiated treatment options.
Non-opioid profile: LX-9211 aligns with continued efforts to expand non-opioid pain management options. If approved, its oral administration and mechanism may influence physician adoption, payer coverage and future treatment guidelines.